Chemotherapy is widely used in various cancer treatments. However, current cancer chemotherapy has a major limitation: lacking of specific targeting ability. As a result, it kills both cancerous and healthy cells, causing severe adverse side-effects and toxicity to patients which limits the dose regime and allows tumour to gain resistance. One approach to address this problem is the development of nanoscale drug delivery systems (NDDSs) which can exploit characteristic properties of tumour, such as the enhanced permeation and retention (EPR) effect, [1] and over-expressed cell-surface receptors, [2] to achieve targeted delivery. [3] Despite significant research achievements, most of the current NDDSs, especially those in clinical trials or usage, e.g. drug encapsulated lipids vesicles or polymer micelles, [4] polymerdrug conjugates, and albumin-based nanoparticles, [5] mostly rely on passive targeting and generally lack the ability of active targeting. Moreover, drugs are mostly physically encapsulated or entrapped into the NDDSs, where drug release is mainly achieved via passive diffusion, making it difficult to achieve controlled release, a vital property for high therapeutic 2 efficacy. As a result, most of the drug payloads may have been released before reaching the target sites, leading to reduced therapeutic efficacy and causing adverse side-effects.
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Furthermore, most NDDSs also suffer from drawbacks such as low drug loading (e.g.
antibody-drug conjugates) and/or burst release (e.g. micelles/liposomes). To date, none of the current NDDSs can satisfy all of the requirements of an "idea NDDS" outlined by Langer et al. [3a] To make best use of the advantages of current NDDSs (passive and active targeting delivery to tumour) and overcome their drawbacks (unnecessary and even harmful on-way drug release before entering tumour cells and/or only a small quantity of drugs together with the nano-carriers entering tumour cells) due to the physical incorporation or encapsulation of drugs in NDDSs, which often leads to uncontrolled drug release via diffusion, we take a new approach to prepare NDDSs which is based on so-called poly(active pharmaceutical ingredient) (PAPI) strategy where the APIs are incorporated into an intracellular cleavable polymer backbone (not physically incorporated in drug carriers) in combination with selfassembly characteristics of amphiphilic block copolymers. Here PAPI is defined as a polymer prepared by polycondensation of an API or its derivative having the same or similar bioactivity as a co-or sole-monomer. Considerable advantages here are that the physicalchemical properties of the PAPIs can be readily tailored by changing co-monomers or via chemical modifications. The PAPIs can be further made into various NDDSs where the API release can be controlled via stimuli triggered polymer degradation, overcoming the drawback of un-controlled, diffusion based drug release character commonly experienced in physically incorporated systems. In principle, any drug molecules/derivatives containing two or more functional groups (e.g. hydroxyl, amine or carboxylic acid) can be exploited to prepare PAPIs.
Similarly, K. Uhrich reports on the chemical conjugation of antibiotics to polymers for localized and sustained drug release, achieved by forming covalent bonds between antibiotics and a pre-existing polymer or by developing novel antibiotic-containing polymers. [6] Curcumin (Cur) is extracted from turmeric as food additive or traditional medicine for centuries in China and India. It has been found that Cur has very low toxicity or even nontoxicity on healthy cells, but selective toxicity on many cancer cells. Cur can be used as chemo-preventive agent, chemo-/radio-sensitizer for tumour cells, as well as chemo-/radioprotector for healthy organs. [7] However, Cur's clinical trials or in vivo applications are limited due to its poor water solubility, poor stability at physiological pH or under UV/Visible radiation. Many efforts have been made to overcome Cur's poor water solubility and instability, such as physical incorporation or encapsulation of Cur within a nanoparticle, conjugation with hydrophilic compounds and copolymerization with hydrophilic monomers. [8] [9] [10] For example, the Shen's group has reported the first polycurcumins by condensation polymerization of curcumin with various hydrophilic PEGs. Such polycurcumin conjugates have the advantages of defined, high drug loading within the polymer backbones, leading to improved curcumin stability and tailored water-solubility. [9] In this paper, Cur containing 2 hydroxyl groups each molecule is used as a model example to demonstrate our PAPI strategy.
We envisaged that an amphiphilic biotin-PEG-b-poly(curcumin-dithiodipropionic acid) (Biotin-PEG-PCDA), consisting of a high molecular weight (MW) hydrophobic PCDA block and a long PEG block, would assemble into stable core-shell nanoparticles (NPs), resulting in greatly increased water-solubility and offering effective protection against recognition and uptake by the reticuloendothelial system, allowing for prolonged circulation and effective tumour targeted accumulation via the EPR effect. Moreover, the hydrophobic core made of PCDA should lead to high drug loading and providing effective protection for Cur against hydrolysis. The Biotin-PEG-PCDA NP should be stable during the blood transport but can readily release its API (Cur) once enters the target cancer cells/tissues triggered by the high intracellular glutathione (GSH, 1-10 mM v.s.~10 M in blood) [11] and esterase [12] contents.
The over-expressed biotin receptors found on cancer cells can be exploited for effective, active cancer targeting. [13] Importantly, the Biotin-PEG-PCDA NP can be loaded with a second anticancer drug (e.g. doxorubicin, Dox) to exploit the synergy of combinational dualdrug therapy to further enhance in vivo anticancer efficacy.
The route to prepare the Biotin-PEG-PCDA NP is shown in Figure 1 schematically. Cur was first copolymerized with dithiodi-propionic acid (DTDPA) to form a hydrophobic PCDA block, which was then coupled to a biotin-PEG to form the amphiphilic biotin-PEG-PCDA diblock copolymer. Details of the synthetic procedures and spectroscopic characterizations of the polymers were given in Supporting Information (SI, Figure S1 and S2, Table S1 ). The
Biotin-PEG-PCDA and PEG-PCDA NPs were prepared by a simple O/W emulsion followed by solvent evaporation method without using emulsifiers or surfactants. For comparison, a poly(L-lactic acid anhydride ester)-b-PEG (Cur-PEG-PAE) NP loaded with Cur via physical encapsulation was also prepared. [14] The biophysical parameters of the NPs were given in SI, Table S2 .
The extremely low water-solubility of free Cur (~0.25 g/mL) has been a major limiting factor for its low bioavailability. As expected, the Biotin-PEG-PCDA and PEG-PCDA prepared here were found to have a much higher water-solubility, being 470 and 360 g/ml (corresponding to 127 and 84 g/ml equivalent of free Cur), respectively. This represents an enhanced solubility of > 500 fold (for Biotin-PEG-PCDA) over free Cur (SI , Table S1 ). Rapid degradation under physiological pH is another major factor limiting free Cur's bioavailability.
This can be monitored by its characteristic absorption at ~420 nm in the UV-vis spectra. As shown in Figure S3 (SI), the UV-vis spectra of Biotin-PEG-PCDA in phosphate buffered saline (PBS, 10 mM phosphate, 150 mM NaCl, pH 7.4) over a course of 24 h were almost identical, with< 5%decrease of absorbance at 400 nm, indicating that the Biotin-PEG-PCDA was stable under such conditions. In contrast, a dramatic decrease (> 50%) of absorbance at 420 nm was observed for free Cur in PBS over 30 min, illustrating a high instability.
Therefore the formation of biotin-PEG-PCDA greatly improved the stability of Cur against hydrolysis by > 500 fold under physiological conditions. The greatly increased solubility and stability of Cur afforded by the PAPI strategy should improve its bioavailability and hence in vivo anti-cancer efficacy.
As described above, GSH can be used as stimulus for triggered intracellular release. As shown in Figure S4 (SI), neither the DLS nor GPC profiles revealed any obviously changes when the Biotin-PEG-PCDA NPs were exposed to PBS without or with low GSH content (10 M), suggesting they were stable under such conditions over the investigated period (3 h), in agreement with the UV-vis data above. In contrast, significantly changes were observed in both the DLS and GPC profiles after exposure of the NPs to PBS containing 5 mM GSH further supported by the observation that HeLa cell uptake of the Biotin-PEG-PCDA NPs was significantly inhibited (by ~55%) by the presence of free biotin (2 mM), while uptake of the PEG-PCDA NP was effectively unaffected (SI, Figure S6D ).
Human cervical (HeLa) and breast (EMT6) cancer cells were used to screen the cytotoxicities of the two NPs ( Figure 2 ). Compared to the PEG-PCDA NP, the Biotin-PEG-PCDA NP exerted significantly higher cytotoxicities against both the HeLa and EMT6 cells.
This result was consistent with a much higher cell uptake of the Biotin-PEG-PCDA NP observed in the flow cytometry measurement. It is worth noting that the PEG-PCDA NP was less cytotoxic than the Cur/PEG-PAE NP (or free Cur) despite both containing flexible and hydrophilic PEG chains which might hinder their cell uptake in a similar degree. However, the physically encapsulated Cur in the PEG-PAE NP could leak out of the carrier during the MTT assay, accounting for a relatively high cytotoxicity. This result implied that the PAPI based Biotin-PEG-PCDA NP should be less toxic towards healthy tissues as well as the blood than the physical encapsulated Cur/PEG-PAE NP, due to high stability under circulating conditions (no drug leak). Moreover, the low levels of biotin receptors in such cells should also minimize non-specific uptake. Another attractive feature of Cur-based chemotherapy is its selective cytotoxicity and low toxicity in vivo: Cur has been reported to have a much higher cytotoxicity against cancer cells over healthy cells, [15a] and moreover, clinical trials have revealed Cur is safe to human even at a high dose of 8 g per day. [7,15b] The fluorescence of PCDA was not strong enough to monitor its in vivo biodistribution. We found however that doxorubicin (DOX), a fluorescent anticancer drug widely used in clinical treatment of various cancers, leukemia and Hodgkin's lymphoma could be readily loaded into the PEG-PCDA NP and used as fluorescence probe for its in vivo biodistribution. [16] After intravenous injection in the EMT6 xenograft mouse model, free DOX was found to primarily accumulate in liver, but rarely in the target tumour throughout the 24 h period ( Figure 3A ). In sharp contrast, significant amounts of the DOX/Biotin-PEG-PCDA NPs were accumulated in the target tumour, which were much higher than those found in other organs such as heart, spleen, lung or kidney. Moreover, the amount of the NPs accumulated in the tumour increased progressively over time, becoming even higher than that in liver after 24 h post injection, The facts that the DOX loaded Biotin-PEG-PCDA NP displayed highly specific tumour targeted accumulation ( Figure 3 ) and released its drug payloads after entering into cancer cells make it ideal to exploit the synergy of combinational dual-drug chemotherapy to maximize treatment efficacy. Indeed, the DOX loaded Biotin-PEG-PCDA NP displayed a remarkably high in vivo anticancer efficacy on ETM6 tumour in mice, which was better than that of the Biotin-PEG-PCDA NP alone ( Figure 5 ). After 6 days of treatment, the tumour size of the dual-drug treated group shrank by ~30% from the starting point of treatment. In contrast, all control groups yielded significant tumour size growths of ~700, ~240 and ~160% after treatment with saline, free DOX and DOX + biotin-PEG-PCDA polymer physical mixture, respectively. This confirmed that the DOX loaded biotin-PEG-PCDA NP was far more effective than the simple physical mixture of the drugs ( Figure 5B ), highlighting the value of our PAPI based nanomedicine in improving therapeutic efficacy in vivo. The significantly improved in vivo anticancer efficacy obtained for the DOX loaded biotin-PEG-PCDA NP may be originated from the synergy of the combined DOX-Cur dual-drug therapy similar to that reported by the Shen group [10a] as well as by us.
[10b] It should be noted that despite numerous studies, most cancer chemotherapy nanomedicines have only managed to inhibit, [17] but not reverse the tumour growth unless being combined with other treatment modalities. [18] The fact that the DOX-loaded biotin-PEG-PCDA NP has successfully reduced the tumour size by 30% after 6 days of treatment demonstrated a real promise of curing cancer by chemotherapy in vivo. In particular, it can be further loaded with other anticancer drugs to exploit the synergy of combinational dual-/multi-drug therapy to maximize the efficacy.
Importantly, all mice groups showed similar levels of continuing body weight gains throughout the course of treatment, implying no significant toxicity effect of the PAPI NPs (SI, Figure S8 ).
In summary, we have developed a new strategy for effective, targeted in vivo cancer chemotherapy by combining the PAPI and NDDS strategies using Cur as a model example.
We have overcome the poor solubility and low stability of free Cur in physiological buffers, a key barrier limiting its in vivo efficacy, by coupling Cur into a disulfide-linked, hydrophobic polymer backbone appended with a terminal PEG-biotin. As a result, the drug's own hydrophobicity has been successfully exploited to initiate stable NP assembly, leading to greatly improved solubility and stability. The resulting PAPI NP offered high drug loading (~27% weight), good stability in physiological buffer, Biotin-medicated high cell uptake and intra-cellular high GSH-/esterase triggered release, overcoming the drawbacks of low drug loading, uncontrolled drug release or leakage during transport often experienced by physical encapsulation based nanomedicines. In particular, the biotinylated PAPI NP displayed a greatly increased, specific, tumour-targeted accumulation, leading to impressive in vivo antitumour efficacy benefited from both the active and passive targeting abilities. The high in vivo anticancer efficacy was found to originate from high degrees of induced apoptosis, antiangiogenic activity and inhibition of cell proliferation. More importantly, the Biotin-PEG-PCDA NP can be loaded with DOX to exploit the synergy of combinational dual chemotherapy, leading to even higher in vivo anticancer efficacy without obvious toxicity.
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Supporting Information is available from the Wiley Online Library. by filtration, the obtained filtrate was added intoan excess of anhydrous ether(1000 mL) to produce a precipitate. The precipitate was further treated by multiple precipitations from dichloromethane with anhydrous ether, and finallydried under vacuum to yield a deep yellow solid product (PCDA, 0.95g,yield ~60%). (0.111g), DMAP (9.9 mg) were dissolved in 40 mL anhydrous dichloromethane. This solution was stirred at room temperature for 24 h. After filtration to remove the formed DCU, the filtrate was added intoan excess of anhydrous ether to produce a precipitate. The precipitate was further treated by multiple precipitations from dichloromethane with anhydrous ether and dried under vacuum to yield the Biotin-PEG as a white solid (1.27 g, yield~90%).
Synthesis of PEG-
PCDA (0.90 g), Biotin-PEG (0.337 g), DCC (22 mg) and DMAP (2 mg) were dissolved in 40 mL anhydrous dichloromethane. The resulting solution was stirred at room temperature for 24 h. After filtration to remove DCU, the filtrate was added intoan excess of anhydrous ether to produce a precipitate. The precipitate was dissolved in water and dialyzed against deionized water for 24 h with a dialysis membrane(MW cut-off of 6000 Da). The Biotin-PEG-PCDAwas obtained as a dry powder after lyophilization(1.03g, yield~83%).
NMR and GPC measurements.
1 H-NMR spectra were measured on a VarianMercury Plus (400 MHz) spectrometer with CDCl 3 as solvent. The chemical shifts were calibrated using tetramethylsilane as an internal standard. GPC measurements were performed at 40 °Con a Waters HPLC system equipped with a model 1525 binary HPLC pump, a model 2414 refractive index detector and a series of Styragelr R columns (HR 3 and HR 4 ).
Tetrahydrofuran was used as an eluent at a flow rate of 1.0 mL/min and the MWs were calibrated with polystyrene standard.
Solubility and stability tests. Solubility of free Cur or the PCDA based polymers was
determined by adding an excess of Cur or polymers into distilled water. The mixture wasvortexed for 10 min to reach solubility equilibrium and centrifuged at 10000 rpm for 5 min. The supernatant was separated and diluted with DMSO for UV measurement at 400 nm (for polymers) or 420 nm (for Cur) on a HITACHI U-2910 spectrophotometer. Free Cur or polymer DMSO solutions were used to generate a standard curve. Stability of Cur or polymers in aqueous media at physiological pH of 7.4 was studied by monitoring the UVvisible absorption spectra of Cur or polymers in aqueous media. stained with 2% phosphotungstic acids and dried before measurement.
Preparation of PEG-PCDA and

Sizes and zeta potential measurements.
The particle size and size distribution ofPEG-PCDA or Biotin-PEG-PCDA NPs were determined by dynamic light scattering (DLS) using a Malvern Instrument Zeta size Nano-S at a detection angle of 173°. All measurements were repeated three times at room temperature. The zeta potential was measured by the light scattering method using a BC Haven instruments corporation 90 plus particle size analyzer.
Curcumin content measurement.
Cur loading content was investigated as previously described, 31 the Cur loading content in PEG-PCDA or Biotin-PEG-PCDA NPs was calculated from the 1 H-NMR spectra using the following equation:
GSH triggered Degradation test. The degradation test of Biotin-PEG-PCDA
wascarried out in phosphate buffered solution (PBS, pH 7.4), PBS with 10 M GSH, and PBS with 5 mM GSH, respectively. 10 mg of Biotin-PEG-PCDA was dissolved in 10 mL of solution and stirred at 37 ºC. At certain time intervals, aliquots of the solution were withdrawn for DLS measurement and then lyophilized. The lyophilized product was dissolved in THF for GPC measurement.
LC-HRMS Analysis of the Biotin-PEG-PCDA NP degradation
Freeze-dried Biotin-PEG-PCDA NP powder (~10 mg) was dissolved in PBS with 5 mM GSH and 100 U esterase. The obtained clear solutionwas then incubated at 37 o C on a shaker for 24 h. After that, the solution was freeze-dried and the resulting dry powder was directly dissolved in chromatographic grade acetonitrile and centrifuged at 13,000 rpm for 30 mins.
The clear supernatant on the top was then analysed by LC-HRMS using the conditions below. 1.11 Cellular uptake. HeLa cells were seeded at a density of 1.5×10 5 cells/mL (2 mL DMEM/well) in 6-well plates and allowed to adhere to the plates for 24 h. After removal of DMEM (with 1% penicillin-streptomycin and 10% FBS), 2 mL of the fresh DMEM with 25 g/mL (equivalentCur) of the PEG-PCDA or Biotin-PEG-PCDA NPs was added into each wells. At the designated time points (after incubation for 0.5, 2, 4, and 24 h), the cells were washed three times with ice-cold PBS, collected by centrifugation and the resuspended in 0.5 mL PBS. The amount of uptake of NPs was measured on a flow cytometer (BD LSRFortessa, Becton Dickinson) using a 405 nm argon laser for excitation and a 515-545 nm emission band-pass filter to detect the fluorescence of Cur. To investigate if free biotin could hinder the biotin receptor mediated endocytosis, HeLa cells were pre-incubated with 2 mM free biotin for 0.5 h before the cells were exposed to the PEG-PCDA or Biotin-PEG-PCDA NPs.
LC-HRMS was
MTT assay.
The in vitro cytotoxicity assays were performed following our earlier procedures. [2] Briefly University.
Ex vivo fluorescence imaging.Ex vivo fluorescence imaging experiments were
performed on a ZKKS-Mulaurora imaging system (Guangzhou ZhongkeKaisheng Medical Technology Co., Ltd, China). In this study, DOX was used as fluorescence probe which was physically incorporated in the NPs. The DOX loaded NPs were prepared as below: water soluble DOX·HClwas first converted to water-insoluble base (DOX)as described previously. [1] 2.5 mg PEG-PCDA (or Biotin-PEG-PCDA) and 0.10 mg DOX were dissolved in 1 mL of methanol and chloroform mixture (12.5 : 87.5 (v/v) ).5 mL of deionized water was slowly poured into the solution and then sonicated at 200 w for 2 min, the power was pulsed for 5s every 30 s to minimize temperature increase. After that, the organic solvent was evaporated by rotary evaporation at 40 °C. The formed NPs solution was obtained by centrifugation at 4000 rpm for 20 min to remove the aggregated particles. The DOX-loaded NPs and free DOX·HCl were injected into mice bearing EMT6 tumor via lateral tail vein (DOX dose:0.5 mg/kg), respectively.The mice were sacrificed at 2, 6, 12 and 24 h postinjection. After which, the major organs or tumors were harvested, and the tissues were imaged onthe ZKKS-Mulaurora imaging system immediately. The ROI (regions of interest) analysis was measured under the assistance of Winmi software. Doxorubicin hydrochloride was first converted to its hydrophobic free base using a previous protocol [1] . The DOX-loaded Biotin-PEG-PCDA NP was prepared by using an emulsion solvent evaporation method. In brief, a solution containing 10 mg of Biotin-PEG-PCDA and 2 mg of DOX in 3 mL of methanol/chloroform solution (12.5:87.5 v/v) with rat anti-mouse CD31 polyclonal antibody (1:50; BD Pharmingen USA), washed twice with PBS, and followed by incubating with a Cy3-conjugated second antibody (Jackson, USA). To study VEGF and COX-2 expression, tumor sections were deparaffinaged in xylene.
After blocking endogenous peroxidase and nonspecific antibody binding, rabbit polyclonal anti-COX-2 antibody or rabbit polyclonal anti-VEGF antibody was diluted at a ratio of 1:200 in 1% bovine albumin-containing PBS and the tumor sections were incubated for 1 h at room temperature. Staining was performed withavidin-biotin reagents, 3,3-diamino-benzidine, and hydrogen peroxide. A secondary biotinylated anti-mouse antibody was added, followed by diaminobenzidine as a chromogen. The tumor sections were lightly counter stained with hematoxylin and examined under light microscopy at ×400 magnifications.
Statistical analysis.
All the experimental data were expressed as means±standard deviation (SD). Statistical analyses were performed using a student's t-tests. The differences between groups are considered as significant for p < 0.05, and very significant for p < 0.01. Angiogenesis has a major role in tumor growth, dissemination and metastasis in solid and hematological tumors. Immunohistochemical assessment using a CD31 staining can be utilized for investigation of tumor vessels in tumor tissue. VEGF is a major pro-angiogenesis factor in tumor Tables   Table S1 . Characterization of the prepared polymers.
*Data in parenthesis: concentrations of equivalent curcumin 
